In 2021, with the COVID-19 pandemic in full swing, BioNTech (NASDAQ:BNTX) and Moderna (NASDAQ:MRNA) were the darlings of the pharma and biotech worlds. The two mRNA therapy developers created ...

Working with mice, hamsters, and nonhuman primates, Penn researchers found that a modified version of the mRNA COVID-19 ...

Moderna – at the moment embroiled in a patent dispute with Pfizer and BioNTech over mRNA intellectual property – is also testing a vaccine that combines COVID-19 and flu in a single jab in a ...

BioNTech, founded in 2008 in Germany, has become a key player in the development of personalized mRNA cancer treatments. The emerging biotech's first commercial vaccine, for covid, received its ...

CureVac – which is developing mRNA-based vaccines for COVID-19 and ... the result of a bid to strike it down filed by BioNTech. The invalidation has come out of the blue for CureVac, which ...

Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Updated COVID-19 vaccines targeting JN.1-lineage omicron variants of the coronavirus are now available in the U.S. for the fall and winter seasons. Here we answer common questions about the latest ...

BioNTech’s top line currently includes sales from its mRNA-based COVID-19 vaccine, Comirnaty, developed in partnership with Pfizer PFE. The vaccine is approved in several countries and has been ...

Welcome to BioNTech's third quarter 2024 earnings call. I would like to hand the call over to Michael Horowicz Director, Investor Relations. Please go ahead.

Presented clinical data for multiple assets across modalities, including bispecific antibody candidate BNT327/PM8002 and mRNA cancer vaccine ...

BioNTech SE, a cutting-edge global immunotherapy company, specializes in developing innovative therapies for cancer and other serious diseases through technologies like mRNA-based vaccines. In its ...

In August 2024, BioNTech and Pfizer provided topline results from the Phase 3 trial (NCT06178991) evaluating the companies’ mRNA combination vaccine candidate in healthy individuals 18-64 ...